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Background: Necrotising enterocolitis (NEC) and late-
onset sepsis (LOS) are the leading causes of death among 
preterm infants in the developed world. This study aimed to 
explore the serum proteome and metabolome longitudinally 
in preterm infants with NEC or LOS, matched to controls.
Methods: Nineteen patients (10 cases, 9 controls) were 
included. A sample 14 d prior to and following, as well as at 
disease diagnosis, was included for cases. Controls had serum 
matched at diagnosis for corresponding case. All samples 
(n = 39) underwent shotgun proteomic analysis, and 37 sam-
ples also underwent metabolomics analysis using ultra perfor-
mance liquid chromatography–tandem mass spectrometry.
results: The proteomic and metabolomic profiles of serum 
were comparable between all infants. Eight proteins were asso-
ciated with NEC and four proteins were associated with LOS. 
C-reactive protein was increased in all NEC patients at diagnosis.
conclusion: No single protein or metabolite was detected 
in all NEC or LOS cases which was absent from controls; how-
ever, several proteins were identified which were associated 
with disease status. The differing expression of these proteins 
between diseased infants potentially relates to differing patho-
physiology of disease. Thus, it is unlikely a single biomarker 
exists for NEC and/or LOS.
necrotising enterocolitis (NEC) and late-onset sepsis (LOS) remain important yet potentially preventable causes of death 
and serious disability in preterm infants (1). Recent compre-
hensive studies of gut bacterial communities have either failed 
to demonstrate or produced inconsistent results, with respect to 
identifying a potential causative organism or reproducible differ-
ences in gut bacterial profiles (2–4). In part, this may be due to 
the multifactorial etiology of NEC and also reflect the challenges 
in making a clinical diagnosis when surgery (and therefore his-
tological confirmation) is not required (5). In addition, LOS 
frequently presents with abdominal distension and raised inflam-
matory markers, yet blood cultures may be negative meaning 
that distinguishing between NEC and LOS is challenging. Even 
though both diseases may involve perturbations in gut bacterial 
communities, preventative measures and treatments differ.
Longitudinal noninvasive (e.g., stool/urine) sampling from 
preterm infants offers the potential to explore disease mecha-
nisms and identify potential biomarkers. In addition, blood can 
be successfully salvaged from preterm infants after routine clini-
cal tests are complete (6). Recent developments in mass spec-
trometry (MS) have facilitated shotgun proteomics on complex 
samples which rely on MS to detect peptides (digested protein) in 
a given sample, overcoming limitations of gel-based approaches. 
Metabolomics is the detection of small molecules (metabolites), 
which are the functional end point of cellular processes. Unlike 
genomics and proteomics, the accurate identification of metab-
olites requires confirmation with known standards and thus 
remains a major limitation of this emerging technology.
Previous work in preterm biomarker research has used 
targeted approaches, identifying many potential biomarkers 
including intestinal fatty acid–binding protein, serum amyloid 
A, and C-reactive protein that have been used alone or in com-
bination, but with little impact to date on clinical care (7–9). 
A recent metabolomic pilot study showed that changes in the 
serum metabolome prior to NEC are associated with upregu-
lation of interleukin-1β (IL-1β), although this study involved 
only five patients (10 samples) with NEC and sample timing 
in relation to NEC was quite varied (10). A two-dimensional 
gel proteomic study of intestinal tissue from premature piglets 
with NEC compared with controls identified 19 differentially 
expressed proteins with functions involving oxidative stress, 
signal transduction, protein folding and degradation, oxygen 
transport, and energy metabolism (11).
The aim of our study was to use proteomic and high-
throughput metabolomic analysis on prospectively collected 
serum from preterm infants diagnosed with NEC or LOS. We 
analyzed longitudinal samples in diseased patients, compared 
with controls matched for gestation, to determine differences 
in the serum proteome and metabolome that might be predic-
tive or indicative of disease.
RESULTS
In total, 447 unique proteins and 24,153 metabolites (16,882 
positively ionised and 7,271 negatively ionised) were detected. 
Known and potentially relevant standards were ran alongside 
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the metabolomic samples, including short-chain fatty acids, 
ceramides, and amino acids but could not be accurately 
matched to identified metabolites from samples. The most 
abundant proteins detected included α-2-macroglobulin, α-1-
antitrypsin, serotransferrin, complement C3, and fibrinogen 
α and β chain. Despite depletion of serum albumin and IgG, 
serum albumin was still found to be the seventh most abun-
dant protein based on relative intensity. Proteins associated 
(i.e., increased in relative intensity) with early samples (<20 
day of life (DOL)) included angiotensinogen, α-fetoprotein, 
and antithrombin-III, whereas the proteins associated with 
the older samples (>21 DOL) included histidine-rich glyco-
protein, C4b-binding protein α chain, calcium-independent 
phospholipase, hemoglobin subunit β, α-1-acid glycoprotein 
1, and leucine-rich α-2-glycoprotein.
As expected, partial least squared discriminatory analysis 
of disease samples matched to controls showed low R2 and 
Q2 scores due to the overall comparability of serum samples 
from disease and control samples (Figure 1). However, the 
proteomic and metabolomic data were in concordance and 
demonstrated that serum from patients 180 and 174, both 
of whom were diagnosed with NEC and underwent surgery, 
were distinct from other serum profiles within this study. The 
protein most associated with these samples was identified as 
transforming growth factor beta induced protein. Notably, 
patient 180 represents the biggest outlier, particularly in the 
metabolomics profiling, and was the only patient who died in 
this cohort.
Samples from both diseased and healthy individuals were 
comparable, and there were no unique proteins or metabolites 
consistently found in only samples from patients with NEC 
or LOS. Supervised modeling of the data revealed that the 
expression of several proteins increased in patients diagnosed 
with NEC and LOS, compared with controls (Supplementary 
Figure S1 online). Eight proteins associated with NEC and 
four proteins associated with LOS in both the between-control 
analysis (phase I) and the within-patient analysis (phase II) are 
listed in Table 1. Notably, the relative abundance of these pro-
teins was not increased in all patients at diagnosis, with some 
patients showing negative correlations and a relative abundance 
lower than the average of all matched controls (Figure  2). 
C-reactive protein was increased in all NEC patients at diagno-
sis and exceeded the average for controls. Ig α-2 chain C region 
levels were increased in 5 out of 6 NEC patients at diagnosis 
(compared to 14 d prior to diagnosis) and had a higher rela-
tive abundance than controls in 4 out of 6 patients. Macrophage 
migration inhibitory factor was also increased in 3 out of 6 
patients with NEC at diagnosis and was above the average con-
trol level in 4 out of 6 patients at diagnosis.
DISCUSSION
Serum Proteome in the Early Stages of Life
α-2-Macroglobulin and α-1-antitrypsin were the two most 
abundant proteins detected in this study, which is in agree-
ment with previous findings from preterm infants in the first 
6 mo of life (12). In accordance with the findings of this study, 
a historical targeted in vivo investigation showed no clear 
association of these two proteins in preterm neonates with 
poor health (13). Similarly, α-fetoprotein levels reduce from 
week 14 of gestation although the synthesis of this protein is 
known to continue following birth (14). Thus, the association 
of α-fetoprotein with early samples likely relates to the prema-
turity of this cohort as suggested by other studies (15).
The proteins associated with samples analyzed later in life 
demonstrate the increasing complexity of the serum proteome 
with age. C4b-binding protein α-chain, which inhibits elements 
of the complement system, is increased in later samples poten-
tially representing increased exposure of the host to potential 
pathogens (2). Like the proteins associated with the early sam-
ples, the proteins associated with the later samples are also in 
accordance with published data, such as α-1-acid  glycoprotein 
1 which increases from infancy to adolescence (16). This agree-
ment with earlier studies suggests that the shotgun metapro-
teomic methodology developed in this study is valid.
Serum Proteome and Metabolome in Health and Disease
Profiling of the serum proteome and metabolome are powerful 
techniques for determining functional changes within a host 
in response to disease. The analysis was split into two phases 
to identify the most robust and reproducible proteins and 
metabolites associated with disease. Phase I explored increased 
expression between diseased and gestationally matched con-
trol infants, and phase II identified those increased within 
patients at disease diagnosis (Figure 3). The serum proteome 
and metabolome were found to be highly conserved within and 
between patients. Thus, no distinct profile was found which 
could robustly predict patients diagnosed with NEC or LOS. 
Furthermore, no unique proteins or metabolites were found 
only in samples representing disease or health. Similarly, in a 
comparable cohort where the urine metabolome was inves-
tigated, no clear difference between NEC and control infants 
was found using ordination analysis, and subsequently, no 
distinct urinary metabolite biomarker that could predict the 
onset on NEC (17).
Eight upregulated proteins were associated with samples 
at NEC diagnosis and four different proteins were associated 
with LOS diagnosis. In accordance with previous  studies, 
upregulation of C-reactive protein and serum amyloid 
A were  associated with the diagnosis of NEC (7–9,18). Here, 
C-reactive protein was upregulated in all NEC patients at diag-
nosis and exceeded the average for controls. This likely demon-
strates increased inflammation in infants who developed NEC 
(9). Using a shotgun metaproteomic approach also facilitated 
the identification of novel proteins not previously reported 
in association with NEC and LOS, including Ig α-2 chain C 
region and macrophage migration inhibitory factor. Increased 
expression of these proteins may relate to increased immune 
response against foreign antigens contributing to NEC (19). 
It  is important to note that in some cases the expression of 
proteins in patients diagnosed with disease was lower than the 
average for the control patients, suggesting that changes of the 
serum proteome in patients with NEC or LOS are specific to 
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the individual or a result of different factors cascading to NEC 
pathogenesis (20). Notably, both the protein and metabolite 
profiles of the only infant to die in this study (patient 180) were 
distinct from the other disease and control infants.
Compared with existing studies in comparable cohorts, we 
find commonality between potentially useful biomarkers for 
the diagnosis of preterm disease; however, no single serum 
biomarker is specific enough to robustly separate the clinical 
manifestation of NEC from controls. The stool microbiota has 
been shown to have important influences on NEC and LOS, but 
the stool microbiota varies vastly within and between infants 
and the “causative organism” differs between studies (2–4). 
Thus, while robust exploration of the direct influence of the 
gut microbiota on the serum proteome is important, statistical 
Figure 1. Partial least squared discriminatory analysis score scatter plot of serum protein and metabolite profiles. DiN show samples at NEC diagnosis 
(red), DiL show samples at LOS diagnosis (purple), and Con show corresponding matched control samples (green). (a) Proteomics. R2 = 0.56, Q2 = −0.15. 
(b) Metabolomics. R2 = 0.73, Q2 = −0.21. LOS, late-onset sepsis; NEC, necrotising enterocolitis.
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validity will require large numbers of infants and time points. 
It is noteworthy that local gut protein and small-molecule bio-
markers in stool may also offer important insights into disease 
pathophysiology; however, to control for proteases and extract 
high-quality stool protein from a functioning neonatal inten-
sive care unit is outside the scope of this study.
Limitations and Future Research Direction
We employed longitudinal sampling at discrete times relative 
to disease to identify new targets that might be used to facili-
tate future biomarker discovery or provide new insights into 
disease pathology. It is however noteworthy that this study 
alone is not sufficiently powered to determine robust biomark-
ers for use in the clinical diagnosis of NEC and LOS. This 
proof-of-concept study also utilized serum that was frozen 
after salvage following routine clinical work, which may result 
in degradation of some proteins. Nevertheless, we feel that 
such opportunistic approaches will be necessary if research in 
NEC and sepsis is to be progressed, especially given the ethical 
challenges posed by invasive sampling and our current inabil-
ity to accurately predict individuals who will develop disease.
table 1. Proteins associated with diagnosis of disease
Accession Protein identification
NEC diagnosis 
associated
P02741 C-reactive protein
Q5VVP7 C-reactive protein (1–205)
A0A075B6N7 Ig α-2 chain C region (fragment)
P07355-2 Isoform 2 of annexin A2
P05451 Lithostathine-1-α
P14174 Macrophage migration inhibitory 
factor
P0DJI9 Serum amyloid A-2 protein
Q15582 Transforming growth factor-β-induced 
protein ig-h3
LOS diagnosis 
associated
A0A087WU08 Haptoglobin
P23634-4 Isoform XK of plasma membrane 
calcium-transporting ATPase 4
A0A087WV45 Transthyretin
O75643 U5 small nuclear ribonucleoprotein 
200 kDa helicase
LOS, late-onset sepsis; NEC, necrotising enterocolitis.
Figure 2. Line graph of longitudinal change within patients with NEC and LOS. Plots show most associated proteins in accordance with Table 2. Protein 
abundance transformed with Log10. NEC samples shown by solid lines in panels (a–h): patients 139 (dark blue diamond), 161 (red square), 171 (green 
triangle), 180 (purple cross), 199 (light blue cross), 174 (orange circle). LOS samples shown by dashed lines in panels (i–l): patients 130 (dark blue diamond), 
166 (red square), 172 (green triangle), 181 (purple cross). Black dotted line represents the average of control data. Each panel represents a different protein: 
(a) C-reactive protein, (b) C-reactive protein (1–205), (c) Ig α-2 chain C region, (d) isoform 2 of annexin A2, (e) lithostathine-1-α, (f) macrophage migration 
inhibitory factor, (g) serum amyloid A-2 protein, (h) transforming growth factor-β-induced protein ig-h3, (i) Haptoglobin, (j) isoform XK of plasma membrane 
calcium-transporting ATPase 4, (k) transthyretin, (l) U5 small nuclear ribonucleoprotein 200 kDa helicase. LOS, late-onset sepsis; NEC, necrotising enterocolitis.
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This study developed an optimized powerful methodology 
for the functional profiling of serum using both proteomics 
and metabolomics. There is great potential for metabolomics 
to detect small molecules in serum, potentially related to func-
tional changes of the host in response to disease. Metabolomics 
still offers important advances in disease understanding for 
independent identification of significant metabolites, even 
when used solely as a profiling technology. Proteomic tech-
nologies offer the advantage of identifying proteins from exist-
ing databases based on peptide matches. Future work should 
build on the findings here, incorporating longitudinal sam-
pling in greater numbers of both disease and control patients. 
Combining multi-omic datasets into systems biology analysis 
will facilitate increased understanding of changes in pathways 
and provides a means of cross-validation between datasets.
Conclusion
No single protein or metabolite was detected in all NEC or LOS 
cases which was absent from controls; however, several proteins 
were identified which were associated with disease status. The 
expression of these proteins generally varied between diseased 
infants, potentially relating to differing pathophysiology of 
disease. Thus, it is unlikely a single biomarker exists for distin-
guishing NEC and/or LOS from healthy infants. Future work 
should aim to better understand the multiple mechanisms that 
lead to NEC or LOS, allowing more accurate classification of 
patients into disease type. This will prevent confounding anal-
ysis based on inaccurate disease classification and may allow 
more specific biomarkers to be developed, accurately predict-
ing the health status of an individual.
METHODS
Ethics Statement
Ethical approval was obtained from the County Durham and Tees 
Valley Research Ethics Committee, and signed informed parental 
informed was obtained.
Infants and Samples
All infants were cared for in the neonatal intensive care unit of the Royal 
Victoria Infirmary, Newcastle upon Tyne, UK, between November 
2011 and August 2012. Standardized feeding, antibiotic, and antifungal 
guidelines were used as described previously (2). Samples were salvaged 
and stored at −20 °C within 72 h as previously described (6). “Cases” had 
confirmed NEC and/or LOS categorized independently by the attending 
clinician and blindly confirmed (J.E.B. or N.D.E.) as described previ-
ously (21). Ten cases were matched with 10 controls based on gestational 
age, although issues in the preparation of serum arose in one control 
case, leaving nine control infants (Table 2). For cases, a sample 14 d (±7) 
prior to disease diagnosis, immediately prior to day of diagnosis (±5), 
and 14 d (±4) after disease diagnosis were analyzed, with the exception 
of patient 139 in whom the last available sample was 3 d post diagnosis 
(Table 2 and Figure 1). Control serum was chosen as close to the day 
of life of the case disease onset as available (±6 d). All samples (n = 39) 
underwent proteomic analysis, and 37 samples also underwent metabo-
lomics analysis, due to insufficient sample remaining for two samples.
Serum Proteomics
A 10 µl aliquot of serum was depleted using the Top 2 abundant pro-
tein depletion spin columns (Pierce, Rockford, IL) for the removal of 
albumin and IgG according to the manufacturers’ instructions. The 
protein concentration was then determined in triplicate using the 
Micro BCA protein assay kit (Pierce) and adjusted to 5 µg in 50 µl with 
25 mmol/l ammonium bicarbonate in siliconized microfuge tubes. 
A 1:1 v/v of 50% sodium deoxycholate was added and incubated on 
ice for 5 minutes to denature the protein (22). The denatured protein 
was diluted in 25 mmol/l ammonium bicarbonate and reduced with 
50  mmol/l dithiothreitol at 60 °C for 30 min. The sample was then 
cooled to room temperature and alkylated with 100 mmol/l iodoacet-
amide at room temperature in the dark for 30 min. To digest the protein, 
5.8 µg/ml of trypsin (Promega, Madison, WI) was added and incubated 
overnight (~16 h) at 37 °C to give a 1:20 trypsin:protein ratio. Following 
the overnight incubation, half the amount of trypsin was added and 
 incubated for a further 2 h to promote further digestion. The reaction 
was stopped by the addition of 10% v/v formic acid, and the sample 
was centrifuged at 16,000g to pellet sodium deoxycholate. The sample 
was freeze-dried and stored at −80 °C until further processing.
A multistep liquid chromatography (LC) gradient was used with 
5% acetonitrile (ACN) increasing to 40% ACN over 180 min, with 
a further 90% ACN for 20 min, followed by a final 10 min re-equil-
ibration at 5% ACN. Samples were run in triplicate, and the order 
of samples in each triplicate sequence was randomized. An Acclaim 
PepMap RSLC C18, 2 µm, 100 Å 50 cm Easy-Spray column (Thermo-
Scientific, Waltham, MA) was used for peptide separation. A 
Q-Exactive (Thermo-Scientific) was used for top10 MS/MS.
Serum Metabolomic Profiling
Water, methanol, and ACN were liquid chromatography mass spec-
trometry (LCMS) grade (Sigma-Aldrich, St Louis, MO). Metabolites 
were extracted from 30 µl serum and homogenized in 120 µl cold 
100% methanol by vortexing for 15 min at 4 °C. The suspension was 
then centrifuged at 10,000g for 10 min at 4 °C and lyophilized in a 
freeze dryer before storage at −80 °C. Samples were re-suspended in 
120 µl of initial start phase buffer (5% ACN). Where 30 µl of sample 
was unavailable, the total volume was recorded, and the volume of 
initial start phase buffer was adjusted accordingly. Serum metabo-
lite profiling was performed using reverse-phase ultraperformance 
LCMS tandem mass spectrometry. A 2.6 µm, 150 × 2.1 mm Accucore 
C18 column (Thermo-Scientific) was used at 40 °C with a 3.0 µl injec-
tion and 300 µl/min flow rate throughout. A multistep LC gradient 
was used with 5% ACN increasing to 95% ACN over 22 min, with a 
further 95% ACN for 4 min followed by a final 4 min re-equilibration 
at 5% ACN. Samples were run in triplicate, and the order of samples 
in each triplicate sequence was randomized. A blank consisting of 
LCMS-grade water underwent the same procedure, and an aliquot 
of every sample was used as a pool. Prior to each run, a blank and 
five pools were processed to equilibrate the system, then blanks and 
pools were processed periodically every 10 samples for background 
subtraction and quality control, respectively. A Q-Exactive (Thermo-
Scientific) was used for the MS, and metabolomic profiling was 
performed using HESI with high-resolution (70,000) positive and 
negative switching. The mass range was set from 100 to 1,000 m/z.
Figure 3. Study design. Numbers on arrows represent the phase of analy-
sis, where phase I determined features associated with disease diagnosis 
compared to control samples and phase II determined features associated 
with disease diagnosis temporally within patients. aLast available sample 
from patient 139 was 3 d post diagnosis.
Pre-Diagnosis
(PrN/PrL)
Diagnosis NEC
(DiN)
Control
(Con)
Post-NEC
(PoN)
Pre-LOS
(PrL)
Diagnosis LOS
(DiL)
2 2
2 2
1
1
Post-LOS
(PoL)
Day −14 (± 7 days) Day 0 (−5 days) Day +14 (± 4a days)
Volume 79  |  Number 3  |  March 2016      Pediatric RESEARCh 429
Official journal of the International Pediatric Research Foundation, Inc.
Articles         Stewart et al.
Data Analysis
Proteomic data were analyzed using Progenesis LC-MS (version 
4.1; Nonlinear Dynamics, Newcastle upon Tyne, UK) detecting 447 
unique proteins in total. Proteins were identified from Progenesis 
LCMS-generated.mgf files by searching the human proteome (uniprot 
2014_10,888,808 sequences) using Mascot version 2.4 (Matrixscience, 
London, UK), trypsin as the digestion enzyme, Cys-carbamidomethyl 
as a fixed modification, and Met-oxidation as a variable modification, 
allowing for one missed cleavage. Peptide tolerance was set to 10 ppm 
and fragment mass tolerance to 10 mmu. Search results were exported 
from mascot in.xml format and imported back into Progenesis 
LC-MS for downsteam analysis.
Metabolomics data were analyzed using Progenesis QI (version 
1.0; Nonlinear Dynamics). Positive and negative data were processed 
individually and combined prior to downstream analysis. Adducts 
contributing >1% relative abundance based on prevalence in the 
pooled samples were selected for the full analysis. Features detected 
after 23 min were ignored, and all features with the highest mean in 
the blank samples were excluded from the analysis.
For all analyses, Progenesis normalization was applied where the 
scaling factor is the anti-log of the mean of the log (ratios). P values 
were generated in Progenesis using ANOVA, where significant fea-
tures were determined based on a probability (P) of <0.05. Features 
associated with disease diagnosis were determined in accordance with 
Figure 1: firstly, features that had a significantly higher mean at disease 
diagnosis compared to controls (phase I) and secondly features which 
increased significantly at diagnosis and decreased thereafter (phase II).
MS1 profiles underwent partial least squared discriminatory analy-
sis using SIMCA 13.0 (Umetrics, Umeå, Sweden) (23). To check that 
data were adhering to multivariate normalities, Hotelling’s T2 toler-
ance limits were calculated and set at 0.95. The R2 and Q2 values for 
partial least squared discriminatory analysis were used to determine 
how reproducible and predictive the data are, respectively, where val-
ues of >0.5 represent a robust model.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/pr
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LOS 181 23 570 Vaginal Breast milk 26 8 25 40
130 27 1,000 Cesarean Breast milk 20 7 20 35
166 29 1,250 Vaginal Breast milk 10 2 10 35
172 28 1,060 Vaginal Breast milk 15 2 15 31
Control 143 24 620 Vaginal Breast milk NA 12
222 24 620 Vaginal Breast milk NA 26
223 24 885 Vaginal Breast milk NA 21
152 25 800 Vaginal Breast milk NA 30
186 26 840 Cesarean Breast milk NA 23
167 27 1,290 Cesarean Formula NA 17
206 28 1,255 Vaginal Breast milk NA 13
208 29 950 Cesarean Breast milk NA 25
207 29 1,580 Cesarean Breast milk NA 10
LOS, late-onset sepsis; NA, not available; NEC, necrotising enterocolitis.
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